Journal Publication

Third-generation EGFR-TKIs tie each other on PFS in network meta-analysis

A pooled analysis of 11 randomized trials and 4,663 patients finds osimertinib, furmonertinib and six other third-generation EGFR-TKIs all beat first-generation drugs, but not each other, on progression-free survival.

By AppliedXLJuly 14, 2026

Executive Summary

A network meta-analysis of first-line EGFR-mutated non-small cell lung cancer trials finds that third-generation EGFR-TKIs as a class extend progression-free survival over first-generation drugs, but no single third-generation agent separates from the others on that measure.
The result establishes parity, not superiority, across the class of newer EGFR-TKIs already used in first-line treatment, extending safety and efficacy findings from individual trials into a pooled comparison.
High-grade treatment-related adverse events did not differ between third- and first-generation drugs in the pooled analysis, reinforcing that the newer agents' benefit comes without an added severe-toxicity trade-off.
Two agents lost their advantage in specific subgroups, showing the class-wide benefit does not hold uniformly across mutation type and age.

The stake

First-line treatment selection for EGFR-mutated non-small cell lung cancer now includes multiple approved third-generation tyrosine kinase inhibitors (TKIs, drugs blocking a cancer growth enzyme), but head-to-head trials comparing them directly are largely absent. The analysis states that comparisons among first-line third-generation agents are nearly absent, which is the gap this pooled analysis was built to address. Progression-free survival, the time before the cancer worsens on treatment, served as the primary efficacy outcome across the pooled trials. First-line

How it was done

The review searched PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials from inception through April 2026, and its protocol was registered with PROSPERO under CRD42022349097. Eligible studies were randomized controlled trials enrolling advanced EGFR-mutated non-small cell lung cancer patients receiving a first-line third-generation EGFR-TKI compared against a first-generation EGFR-TKI. Two reviewers independently extracted data and assessed risk of bias using the Cochrane RoB 2 tool, and the analysis pooled 11 trials totaling 4,663 patients using a fixed-effect network meta-analysis, ranking agents by surface under the cumulative ranking curve (SUCRA). First-line

The result

All eight third-generation agents analyzed, aumolertinib, osimertinib, furmonertinib, befotertinib, limertinib, rilertinib, lazertinib, and rezivertinib, showed superior progression-free survival compared with first-generation TKIs. None of the third-generation agents showed a statistically significant progression-free survival difference against any other third-generation agent. Objective response rate and grade 3 or higher treatment-emergent adverse events also showed no statistically significant differences between the two generations. First-line

Where the class benefit narrowed

Subgroup analyses found befotertinib did not show a statistically significant progression-free survival benefit over first-generation TKIs in patients with the L858R mutation, and neither befotertinib nor furmonertinib showed a statistically significant benefit over first-generation TKIs in elderly patients. These exceptions sit inside an otherwise consistent class-wide advantage and mark where the pooled effect did not fully generalize across mutation subtype and age. First-line

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.